Differences in White Blood Cells, Neutrophil-to-Lymphocyte Ratio, Tumor Necrosis Factor-α based on Procalcitonin Level in Community-Acquired Pneumonia Patients
Abstract
Background: Community-acquired pneumonia (CAP) is a respiratory infectious disease caused by bacteria, viruses, or fungi. Procalcitonin (PCT) levels will rise, especially in bacterial infection. PCT examination in CAP can help to confirm the diagnosis and anticipate complications. CAP is diagnosed by symptoms, vital signs, laboratory tests, and radiographic investigations. Inflammatory biomarkers are required for predicting causative microorganisms, guiding antibiotic therapy, and determining severity. The purpose of this study is to compare NLR, WBC, and TNF-α levels in CAP patients dependent on PCT level.
Methods: This was an analytical cross-sectional study involving 43 CAP patients admitted to Universitas Sebelas Maret (UNS) Hospital and Moewardi Regional General Hospital Surakarta between February and March 2023. Patients were separated into two groups based on PCT levels: those with levels ≤0.12 ng/mL and >0.12 ng/mL. All patients provided a blood sample for NLR, WBC, TNF-α, and PCT testing. The independent t-test and Mann-Whitney tests were performed for statistical analysis of two unpaired groups, and the Chi-square or Fisher exact test was utilized for ordinal categorical data. If the value of P<0.05, the result is statistically significant.
Results: NLR and TNF-α levels were higher in the PCT group >0.12 ng/mL and statistically significant with a value of P=0.001. WBC levels in the PCT group >0.12 ng/mL were higher, but the difference was not statistically significant (P=0.096).
Conclusion: The NLR value, WBC, and TNF-α levels were found to be higher in the group with PCT >0.12 ng/mL.
Keywords
Full Text:
PDFReferences
Çil E, Karadeniz G, Yenigün S, Çorapli G. Evaluation of the relationships between procalcitonin and neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in patients with pneumonia. Eur Rev Med Pharmacol Sci. 2022;26(9):3200–5.
Ito A, Ishida T. Diagnostic markers for community-acquired pneumonia. Ann Transl Med. 2020;8(9):609.
Wang W, Zhu Y, Yin L, Deng Y, Chu G, Liu S. Utilization of serum procalcitonin as a biomarker in the diagnosis and treatment of children with bacterial hospital-acquired pneumonia. Mol Cell Biochem. 2021;476(1):261–7.
Siljan WW, Holter JC, Michelsen AE, Nymo SH, Lauritzen T, Oppen K, et al. Inflammatory biomarkers are associated with aetiology and predict outcomes in community-acquired pneumonia: Results of a 5-year follow-up cohort study. ERJ Open Res. 2019;5(1):00014–2019.
Gardner JG, Bhamidipati DR, Rueda AM, Nguyen DTM, Graviss EA, Musher DM. White blood cell counts, alcoholism, and cirrhosis in pneumococcal pneumonia. Open Forum Infect Dis. 2017;4(2):ofx034.
Kuikel S, Pathak N, Poudel S, Thapa S, Bhattarai SL, Chaudhary G, et al. Neutrophil–lymphocyte ratio as a predictor of adverse outcome in patients with community-acquired pneumonia: A systematic review. Health Sci Rep. 2022;5(3):e630.
Ozbay S, Ayan M, Ozsoy O, Akman C, Karcioglu O. Diagnostic and prognostic roles of procalcitonin and other tools in community-acquired pneumonia: A narrative review. Diagnostics. 2023;13(11):1869.
Li L, Nie W, Li W, Yuan W, Huang W. Associations between TNF-α polymorphisms and pneumonia: A meta-analysis. PLoS One. 2013;8(4):e61039.
Yang T, Wan C, Wang H, Qin J, Chen L, Shen Y, et al. The prognostic and risk-stratified value of neutrophil-lymphocyte count ratio in Chinese patients with community-acquired pneumonia. Eur J Inflamm. 2017;15(1):22–7.
Savvateeva EN, Rubina AY, Gryadunov DA. Biomarkers of community-acquired pneumonia: A key to disease diagnosis and management. Biomed Res Int. 2019;2019:1701276.
Perhimpunan Dokter Paru Indonesia. Pneumonia kominitas, pedoman diagnosis & penatalaksanaan di Indonesi. 2nd ed. Jakarta: FKUI; 2014.
Liu D, Su LX, Guan W, Xiao K, Xie LX. Prognostic value of procalcitonin in pneumonia: A systematic review and meta-analysis. Respirology. 2016;21(2):280–8.
Andrijevic I, Matijasevic J, Andrijevic L, Kovacevic T, Zaric B. Interleukin-6 and procalcitonin as biomarkers in mortality prediction of hospitalized patients with community acquired pneumonia. Ann Thorac Med. 2014;9(3):162–7.
Jin Z, Cai G, Zhang P, Li X, Yao S, Zhuang L, et al. The value of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as complementary diagnostic tools in the diagnosis of rheumatoid arthritis: A multicenter retrospective study. J Clin Lab Anal. 2021;35(1):e23569.
Buonacera A, Stancanelli B, Colaci M, Malatino L. Neutrophil to lymphocyte ratio: An emerging marker of the relationships between the immune system and diseases. Int J Mol Sci. 2022;23(7):3636.
Ng WWS, Lam SM, Yan WW, Shum HP. NLR, MLR, PLR and RDW to predict outcome and differentiate between viral and bacterial pneumonia in the intensive care unit. Sci Rep. 2022;12(1):15974.
Ratageri VH, Panigatti P, Mukherjee A, Das RR, Goyal JP, Bhat JI, et al. Role of procalcitonin in diagnosis of community acquired pneumonia in Children. BMC Pediatr. 2022;22(1):217.
Williams DJ, Hall M, Auger KA, Tieder JS, Jerardi KE, Queen MA, et al. Association of white blood cell count and C-reactive protein with outcomes in children hospitalized for community-acquired pneumonia. Pediatric Infectious Disease Journal. 2015;34(7):792–3.
Li Y, Min L, Zhang X. Usefulness of procalcitonin (PCT), C-reactive protein (CRP), and white blood cell (WBC) levels in the differential diagnosis of acute bacterial, viral, and mycoplasmal respiratory tract infections in children. BMC Pulm Med. 2021;21(1):386.
Paats MS, Bergen IM, Hanselaar WEJJ, Van Zoelen ECG, Hoogsteden HC, Hendriks RW, et al. Local and systemic cytokine profiles in nonsevere and severe community-acquired pneumonia. European Respiratory Journal. 2013;41(6):1378–85.
Krüger S, Ewig S, Papassotiriou J, Kunde J, Marre R, von Baum H, et al. Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP - Results from the German competence network CAPNETZ. Respir Res. 2009;10:65.
DOI: https://doi.org/10.36497/jri.v44i3.632
Refbacks
- There are currently no refbacks.
Copyright (c) 2024 Yusup Subagio Sutanto, Hendrastutik Apriningsih, Akhmad Syaikhu, Sihsusetyaningtyas Tiominar Siregar
INDEXING & PARTNER
Jurnal Respirologi Indonesia pISSN: 0853-7704 - eISSN: 2620-3162 Address: Jalan Cipinang Bunder No. 19, Cipinang, Pulogadung, Jakarta Timur, DKI Jakarta 13240, Indonesia Phone: +62-21-2247-4845 Email: editor@jurnalrespirologi.org | An official publication by the Indonesian Society of Respirology (ISR) |
Creative Commons Attribution-ShareAlike 4.0 International License Statcounter |